ABVC BioPharma, Inc.

NasdaqCM:ABVC Stock Report

Market Cap: US$6.2m

ABVC BioPharma Past Earnings Performance

Past criteria checks 0/6

ABVC BioPharma's earnings have been declining at an average annual rate of -14.3%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 8.1% per year.

Key information

-14.3%

Earnings growth rate

5.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-8.1%
Return on equity-109.3%
Net Margin-1,617.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

Mar 13
ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Oct 05

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

Sep 23

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Aug 18
ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

Aug 17

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

Jul 13

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

Jun 30

Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?

Apr 04
Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?

Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?

Dec 09
Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?

Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?

Aug 05
Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?

Revenue & Expenses Breakdown

How ABVC BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:ABVC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-860
30 Jun 240-1180
31 Mar 240-1391
31 Dec 230-1171
30 Sep 231-1272
30 Jun 231-1393
31 Mar 231-1293
31 Dec 221-16133
30 Sep 220-19171
30 Jun 220-18161
31 Mar 220-18161
31 Dec 210-13111
30 Sep 210-10101
30 Jun 210-1091
31 Mar 211-1091
31 Dec 200-1081
30 Sep 201-651
30 Jun 201-541
31 Mar 201-441
31 Dec 191-431
30 Sep 191-631
30 Jun 190-621
31 Mar 190-621
31 Dec 180-621
30 Sep 180-210
30 Jun 180-513
31 Mar 180-513
31 Dec 170-413
30 Sep 170-413
30 Jun 170-110
31 Mar 170-110
31 Dec 160-817
30 Sep 160-11110
31 Dec 150-524

Quality Earnings: ABVC is currently unprofitable.

Growing Profit Margin: ABVC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ABVC is unprofitable, and losses have increased over the past 5 years at a rate of 14.3% per year.

Accelerating Growth: Unable to compare ABVC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABVC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: ABVC has a negative Return on Equity (-109.25%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 23:49
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ABVC BioPharma, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group
Marla MarinZacks Small-Cap Research